Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefazolin + tobramycin is a combination of two antibiotics frequently used in clinical practice, especially as fortified topical solutions for the treatment of serious bacterial infections such as bacterial keratitis (corneal ulcers) and peritoneal dialysis-related peritonitis. Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis, primarily targeting Gram-positive organisms. Tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting protein synthesis and providing broad-spectrum activity against many Gram-negative bacteria. The combination offers synergistic or additive antibacterial effects, expanding coverage across both Gram-positive and Gram-negative pathogens[1][3][5]. This regimen is often chosen when broad empirical coverage is needed or when resistance patterns necessitate dual therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefazolin + tobramycin.